FDA: Vytorin Unlikely to Up Cancer Risk
Links shared publicly online about this topic.
- 1,511total visits
FDA: Vytorin Unlikely to Up Cancer Risk
View full resource at webmd.com
Tags: Cholesterol Medication, Cancer, Drug, FDA, Vytorin
Most Recently Shared on December 23, 2009 at 1:02 am By:
FDA: Vytorin Unlikely to Up Cancer Risk: The FDA has backed off a 2008 statement describing a possible link between... http://bit.ly/4PbWLG
Also Shared By:
FDA: Vytorin Unlikely to Up Cancer Risk - Tom Heston
tomheston.com — “FDA: Vytorin Unlikely to Up Cancer Risk - Tom Heston” View full resource at tomheston.com
Most Recently Shared on December 24, 2009 at 4:21 am By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
FDA: Vytorin Unlikely to Up Cancer Risk http://bit.ly/7UDXMz
FDA: Vytorin Unlikely to Up Cancer Risk
tweetmeme.com — “The FDA has backed off a 2008 statement describing a possible link between use of the cholesterol-lowering drug Vytorin and cancer, saying any connection is unlikely but shouldn't be ruled out.” View full resource at tweetmeme.com
Most Recently Shared on December 23, 2009 at 3:48 pm By:
Healthcare TweetMeme Health Social Media
FDA: Vytorin Unlikely to Up Cancer Risk http://retwt.me/1Lddk (via @rashmigupta2100)
FDA: Vytorin Unlikely to Up Cancer Risk
tweetmeme.com — “The FDA has backed off a 2008 statement describing a possible link between use of the cholesterol-lowering drug Vytorin and cancer, saying any connection is unlikely but shouldn't be ruled out.” View full resource at tweetmeme.com
Most Recently Shared on December 23, 2009 at 2:50 am By:
Healthcare TweetMeme Health Social Media
FDA: Vytorin Unlikely to Up Cancer Risk http://retwt.me/1LcGZ (via @WellnessInfo)
Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial
fda.gov — “In august 2008, the u.s. food and drug administration (fda) issued an early communication describing a possible association between the use of vytorin – a combination of simvastatin (zocor) and ezetimibe (zetia) – and an increased risk of cancer and cancer-related death compared to placebo.” View full resource at fda.gov
Most Recently Shared on December 22, 2009 at 4:31 pm By:
eyeonfda Pharma and Health Lawyer
RT @FDA_Drug_Info: Follow-Up to the Aug. 2008 Early Communication on Vytorin, Zetia, Zocor and the SEAS Trial. http://bit.ly/FU_SEAS
Advertisement
WebMD_News
@WebMD_News
FDA: Vytorin Unlikely to Up Cancer Risk: The FDA has backed off a 2008 statement describing a possible link between... http://bit.ly/4PbWLG
1 year ago...